The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
Ranee Mehra
No relevant relationships to disclose
D. Ross Camidge
Consultant or Advisory Role - Novartis
Sunil Sharma
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Enriqueta Felip
No relevant relationships to disclose
Daniel Shao-Weng Tan
Research Funding - Novartis
Johan F. Vansteenkiste
No relevant relationships to disclose
Tommaso Martino De Pas
Honoraria - Novartis
Dong-Wan Kim
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Geoffrey Liu
No relevant relationships to disclose
Meredith Goldwasser
Employment or Leadership Position - Novartis
David Dai
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marietta Radona
Employment or Leadership Position - Novartis
Anthony Boral
Employment or Leadership Position - Novartis Institutes for Biomedical Research
Stock Ownership - Novartis
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Novartis; Pfizer